Xanomeline/Trospium Chloride Shows Cognitive Improvement in Schizophrenia; MindMed's LSD Trial Begins
Key Insights
Xanomeline/trospium chloride (search) (Cobenfy) improved cognition in schizophrenia (search) patients with baseline cognitive impairment, according to an exploratory analysis of two phase III trials.
MindMed (search) initiated a phase III trial of lysergide D-tartrate (LSD) for generalized anxiety disorder (search), marking the first phase III trial for LSD.
Reviva Pharmaceuticals reported that brilaroxazine significantly reduced PANSS total score in schizophrenia (search) patients after 52 weeks in a long-term extension study.
An exploratory analysis of two phase III trials indicates that xanomeline/trospium chloride (search) (Cobenfy) improved cognition in patients with acute schizophrenia (search) who had clinically significant cognitive impairment at baseline. The findings, published in the American Journal of Psychiatry, suggest a potential therapeutic avenue for addressing cognitive deficits in schizophrenia.
Xanomeline/Trospium Chloride for Cognitive Impairment in Schizophrenia
The study involved patients with acute schizophrenia (search) and clinically significant baseline cognitive impairment. Results showed that xanomeline/trospium chloride (search) led to cognitive improvements in this patient population. These findings highlight the potential of this drug combination to address a critical unmet need in schizophrenia treatment, as cognitive deficits are a major contributor to functional disability.
MindMed's LSD Trial for Generalized Anxiety Disorder
MindMed (search) has announced the commencement of a phase III trial for lysergide D-tartrate (LSD), a pharmaceutically optimized form being investigated as a potential treatment for generalized anxiety disorder (search) (GAD). This marks the first phase III trial for LSD. The Phase IIb findings were previously presented at the American Psychiatric Association annual meeting earlier this year.
Brilaroxazine Shows Promise in Schizophrenia
Reviva Pharmaceuticals announced positive preliminary topline data from the long-term open-label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia (search). The strongest dose of once-daily investigational brilaroxazine decreased Positive and Negative Syndrome Scale (PANSS) total score by 20.8 points in patients with schizophrenia at 52 weeks.
Duloxetine (Cymbalta) Recall
Over 230,000 bottles of the antidepressant duloxetine (Cymbalta) have been recalled due to the presence of a potential carcinogen.